½ÃÀ庸°í¼­
»óǰÄÚµå
1600441

Á¦»êÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Á¦Çüº°, ÀûÀÀÁõº°, À¯Åë ä³Îº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Antacids Market by Drug Class (Acid Neutralizers, H2 Antagonist, Promotility Agents), Formulation (Liquid, Powder, Tablet), Indication, Distribution Channel - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Á¦»êÁ¦ ½ÃÀåÀº 2023³â¿¡ 68¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 72¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.81%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 101¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¦»êÁ¦ ½ÃÀå¿¡´Â À§»êÀ» ÁßÈ­½Ã۰í À§»ê ¿ª·ù, ¼ÒÈ­ºÒ·®, ¼Ó¾²¸²°ú °ü·ÃµÈ Áõ»óÀ» ¿ÏÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ´Ù¾çÇÑ ÀϹÝÀǾàǰ°ú 󹿾àÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. Á¦»êÁ¦ÀÇ Çʿ伺Àº °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°ü, ½ºÆ®·¹½º, ÁÂ½Ä »ýȰ µî »ýȰ½À°ü ¿äÀÎÀ¸·Î ÀÎÇÑ À§ÀåÁúȯÀÌ ³Î¸® ÆÛÁ® Àֱ⠶§¹®ÀÔ´Ï´Ù. Á¦»êÁ¦ÀÇ ¿ëµµ´Â ÁÖ·Î ÀÇ·á ¹× Á¦¾à »ê¾÷¿¡¼­ ¼ÒÈ­±â ÁúȯÀÇ ºÒÆíÇÔÀ» Áï½Ã ¿ÏÈ­ÇØ¾ß ÇÏ´Â ¼ÒºñÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù. Á¦»êÁ¦´Â ³ëÀÎ, ÀÓ»êºÎ, ¸¸¼º À§Àå ¹®Á¦¸¦ °¡Áø »ç¶÷ µî ´Ù¾çÇÑ °èÃþ¿¡¼­ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. À§Àå °Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÚ°¡ Ä¡·á µ¿Çâ Áõ°¡, ´Ù¾çÇÑ ¿¬·ÉÃþ¿¡°Ô ¾îÇÊÇÒ ¼ö ÀÖ´Â Ãò¾îºí Á¤Á¦¿Í ÇâÀÌ Ã·°¡µÈ Á¦Ç°µéÀÇ ÀαⰡ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 68¾ï 5,000¸¸ ´Þ·¯
¿¹Ãø³â[2024] 72¾ï 4,000¸¸ ´Þ·¯
¿¹Ãø³â[2030] 101¾ï 8,000¸¸ ´Þ·¯
CAGR(%) 5.81%

ÁÖ¿ä ¿µÇâ¿äÀÎÀº Àü ¼¼°è À§ÀåÁúȯ Áõ°¡·Î ÀÎÇÑ ¼ÒÈ­±â °Ç°­ ½ÃÀåÀÇ ±Þ°ÝÇÑ ¼ºÀåÀÔ´Ï´Ù. ÀáÀçÀûÀÎ ¼ºÀå ±âȸ´Â Áß»êÃþ Àα¸°¡ Áõ°¡ÇÏ°í °Ç°­°ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö´Â ½ÅÈï ½ÃÀå¿¡¼­ ãÀ» ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¹«¼³ÅÁ, ºñ°Ç, À¯±â³ó µî °Ç°­À» Áß½ÃÇÏ´Â ¼ÒºñÀÚµéÀ» À§ÇÑ Çõ½ÅÀûÀÎ Á¦Ç° °³¹ß¿¡ ÅõÀÚÇØ¾ß ÇÕ´Ï´Ù. ±×·¯³ª ±ÔÁ¦ À庮, Àå±â »ç¿ëÀ¸·Î ÀÎÇÑ ºÎÀÛ¿ë °¡´É¼º, ¾ç¼ºÀÚ ÆßÇÁ ¾ïÁ¦Á¦ ¹× H2 ¼ö¿ëü ±æÇ×Á¦¿Í °°Àº ´ëü Ä¡·áÁ¦¿Í °æÀïÇÏ´Â µîÀÇ ¹®Á¦´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ À߸øµÈ Á¤º¸¿Í ÀûÀýÇÑ »ç¿ë¹ý¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·À¸·Î ÀÎÇØ ¼ÒºñÀÚµéÀÌ È¥¶õ½º·¯¿ö ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ Á¦¾àÀ» ±Øº¹Çϱâ À§Çؼ­´Â ¿ÏÈ­ ½Ã°£À» ¿¬ÀåÇϰí, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϸç, ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â ¿¬±¸°³¹ßÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ ¼ÓÈ¿¼º ¾×ü Á¦Á¦³ª ¿ëÇØ¼º ½ºÆ®¸³°ú °°Àº Àü´Þ ¸ÞÄ¿´ÏÁòÀ» °­È­ÇÏ´Â °Íµµ °æÀï·ÂÀ» ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. Á¦»êÁ¦ È­ÇÕ¹°°ú Àå³»¼¼±ÕÃÑÀÇ »óÈ£ÀÛ¿ë¿¡ ´ëÇÑ Ã·´Ü ¿¬±¸´Â °³ÀÎÈ­µÈ ¼ÒÈ­±â Ä¡·á¸¦ À§ÇÑ ¹Ì°³¹ßµÈ ÀáÀç·ÂÀ» Á¦°øÇÕ´Ï´Ù. Á¦»êÁ¦ ½ÃÀåÀº ¿ªµ¿ÀûÀÌ°í ¼ÒºñÀÚ ÁÖµµÀûÀ̱⠶§¹®¿¡ ±ÔÁ¦¿Í °æÀïÀÇ µµÀüÀ» ±Øº¹ÇÏ°í ¼ÒºñÀÚÀÇ ´ÏÁî¿Í ¼±È£µµ º¯È­¿¡ ´ëÀÀÇϱâ À§ÇØ Áö¼ÓÀûÀÎ Çõ½Å°ú Àü·«Àû ¸¶ÄÉÆÃÀÌ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Á¦»êÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Á¦»êÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«Àû ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • À§½Äµµ ¿ª·ùÁúȯ ȯÀÚ Áõ°¡
    • ¼¼°è °¢±¹ Á¤ºÎÀÇ ±¹³» ÀǾàǰ Á¦Á¶¿¡ ´ëÇÑ ³ë·Â°ú ÅõÀÚ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • »ê°ú °ü·ÃµÈ ¹®Á¦¿¡ ´ëÇÑ °¡Á¤ ¿ä¹ý ¹× ±âŸ ´ëüǰÀÇ °¡¿ë¼º
  • ½ÃÀå ±âȸ
    • º¸´Ù Áï°¢ÀûÀ̰í Áö¼Ó¼ºÀÌ ³ôÀº Á¦»êÁ¦ °³¹ß
    • ¿Â¶óÀÎ ¾à±¹¿¡¼­ Á¦»êÁ¦¸¦ ½±°Ô ±¸ÇÒ ¼ö ÀÖ°í OTC ÀǾàǰ¿¡ ´ëÇÑ ±ÔÁ¦ÀÇ À¯¿¬¼ºÀÌ ÀÖÀ½
  • ½ÃÀå °úÁ¦
    • Á¦»êÁ¦ °ü·Ã ÀǾàǰ ȸ¼ö ¹× ¿À¿° ¹®Á¦

Portre's Five Forces: Á¦»êÁ¦ ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« Åø

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Á¦»êÁ¦ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Á¦»êÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Á¦»êÁ¦ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Á¦»êÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º Á¦»êÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Á¦»êÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·«Àû ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Á¦»êÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

  • »êÁßÈ­Á¦
    • ¼ö»êÈ­ ¾Ë·ç¹Ì´½
    • ź»êÄ®½·
    • ¼ö»êÈ­ ¸¶±×³×½·
    • Áßź»ê³ªÆ®·ý
  • H2 ±æÇ×Á¦
  • ÇÁ·Î¸ð¼Ç ¿¡ÀÌÀüÆ®
  • ÇÁ·ÎÅæÆßÇÁ ÀúÇØÁ¦

Á¦7Àå Á¦»êÁ¦ ½ÃÀå : ó¹æº°

  • ¾×ü
  • ºÐ¸»
  • Á¤Á¦

Á¦8Àå Á¦»êÁ¦ ½ÃÀå : ÀûÀÀÁõº°

  • À§½Äµµ ¿ª·ùÁõ
  • ¼ÒÈ­ºÒ·®/¼ÒÈ­ºÒ·®
  • ¼ÒÈ­¼º ±Ë¾ç

Á¦9Àå Á¦»êÁ¦ ½ÃÀå : À¯Åë ä³Îº°

  • º´¿ø ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • ¼Ò¸Å ¾à±¹

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Á¦»êÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¦»êÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¦»êÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Abbott Laboratories
  • Aero Healthcare AU Pty Ltd
  • Alcon Industries
  • Alkem Laboratories Ltd.
  • Allegiant Health
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Camber Pharmaceuticals, Inc.
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Dexcel Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline PLC
  • Haleon PLC
  • Imerys S.A.
  • J. B. Chemicals & Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Magmit Pharmaceutical Co., Ltd.
  • Mankind Pharma Ltd.
  • Marksans Pharma
  • Nestle S.A.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Raritan Pharmaceuticals, Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Swiss Chem Healthcare by Swastik Lifesciences
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • The Procter & Gamble Company
  • Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals
  • Wonderbelly
  • Zoic Pharmaceuticals Pvt. Ltd.
KSA 24.12.05

The Antacids Market was valued at USD 6.85 billion in 2023, expected to reach USD 7.24 billion in 2024, and is projected to grow at a CAGR of 5.81%, to USD 10.18 billion by 2030.

The antacids market encompasses a wide range of over-the-counter and prescription medications intended to neutralize stomach acidity and alleviate symptoms associated with acid reflux, indigestion, and heartburn. The necessity of antacids stems from the widespread prevalence of gastrointestinal diseases caused by lifestyle factors such as unhealthy diets, stress, and sedentary habits. Their application is primarily within the healthcare and pharmaceutical industries, targeting consumers in need of immediate relief from digestive discomfort. Antacids are used by a diverse demographic, including older adults, pregnant women, and individuals with chronic gastrointestinal issues. The market's growth is fueled by rising awareness of gastrointestinal health, increased self-medication trends, and the rising popularity of chewable tablets and flavored versions that appeal to a broader audience.

KEY MARKET STATISTICS
Base Year [2023] USD 6.85 billion
Estimated Year [2024] USD 7.24 billion
Forecast Year [2030] USD 10.18 billion
CAGR (%) 5.81%

A key influencing factor is the burgeoning digestive health market, driven by the increase in gastrointestinal diseases globally. Potential growth opportunities reside in emerging markets with a rising middle-class population and increasing healthcare awareness. Companies should invest in innovative product formulations like sugar-free, vegan-friendly, and organic antacids that cater to health-conscious consumers. However, challenges such as regulatory hurdles, the potential side effects of long-term use, and competition from alternative treatments like proton pump inhibitors and H2-receptor antagonists may hinder market growth. Furthermore, misinformation and a lack of awareness regarding appropriate usage can lead consumers astray.

To overcome these limitations, research can be directed towards developing antacids with extended relief duration, minimal side effects, and improved patient compliance. Enhanced delivery mechanisms like fast-acting liquid formulations or dissolvable strips could also provide a competitive edge. Advanced studies on gut microbiota interactions with antacid compounds offer untapped potential for personalized digestive care. The antacids market is dynamic and consumer-driven, requiring continuous innovation and strategic marketing to cater to varying consumer needs and preferences while navigating the challenges posed by regulation and competition.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antacids Market

The Antacids Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing population suffering from gastroesophageal reflux disease
    • Government initiatives and investments for domestic drug manufacturing worldwide
  • Market Restraints
    • Availability of home remedies and other alternatives for acidity-related issues
  • Market Opportunities
    • Development of more instantly effective and long-lasting antacids
    • Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
  • Market Challenges
    • Drug recall and contamination issues associated with the antacids

Porter's Five Forces: A Strategic Tool for Navigating the Antacids Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antacids Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antacids Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antacids Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antacids Market

A detailed market share analysis in the Antacids Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antacids Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antacids Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antacids Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Aero Healthcare AU Pty Ltd, Alcon Industries, Alkem Laboratories Ltd., Allegiant Health, AstraZeneca plc, Bayer AG, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals, Inc., Cipla Limited, Daiichi Sankyo Company Limited, Dexcel Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline PLC, Haleon PLC, Imerys S.A., J. B. Chemicals & Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Magmit Pharmaceutical Co., Ltd., Mankind Pharma Ltd., Marksans Pharma, Nestle S.A., Novartis AG, Perrigo Company plc, Pfizer Inc., Raritan Pharmaceuticals, Inc., Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Swiss Chem Healthcare by Swastik Lifesciences, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., The Procter & Gamble Company, Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals, Wonderbelly, and Zoic Pharmaceuticals Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Antacids Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Acid Neutralizers, H2 Antagonist, Promotility Agents, and Proton Pump Inhibitor. The Acid Neutralizers is further studied across Aluminum Hydroxide, Calcium Carbonate, Magnesium Hydroxide, and Sodium Bicarbonate.
  • Based on Formulation, market is studied across Liquid, Powder, and Tablet.
  • Based on Indication, market is studied across Gastroesophageal Reflux Disease, Indigestion/Dyspepsia, and Peptic Ulcer Disease.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing population suffering from gastroesophageal reflux disease
      • 5.1.1.2. Government initiatives and investments for domestic drug manufacturing worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of home remedies and other alternatives for acidity-related issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of more instantly effective and long-lasting antacids
      • 5.1.3.2. Easy availability of antacids in the online pharmacy and regulation flexibility for OTC drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Drug recall and contamination issues associated with the antacids
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Increasing preference for acid neutralizers for improved therapeutic action
    • 5.2.2. Indication: Expanding need for antacids for the management of gastroesophageal reflux disease for reducing the acid's ability to damage the esophageal lining.
    • 5.2.3. Formulation: Rising preference for liquid antacid due to their already dissolved state, facilitating quicker relief from symptoms
    • 5.2.4. Distribution Channel: Growing availability of antacids across retail pharmacies that provide instant access to antacids without the need for a prescription
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antacids Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Acid Neutralizers
    • 6.2.1. Aluminum Hydroxide
    • 6.2.2. Calcium Carbonate
    • 6.2.3. Magnesium Hydroxide
    • 6.2.4. Sodium Bicarbonate
  • 6.3. H2 Antagonist
  • 6.4. Promotility Agents
  • 6.5. Proton Pump Inhibitor

7. Antacids Market, by Formulation

  • 7.1. Introduction
  • 7.2. Liquid
  • 7.3. Powder
  • 7.4. Tablet

8. Antacids Market, by Indication

  • 8.1. Introduction
  • 8.2. Gastroesophageal Reflux Disease
  • 8.3. Indigestion/Dyspepsia
  • 8.4. Peptic Ulcer Disease

9. Antacids Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Antacids Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Antacids Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Antacids Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. TUMS Teams Up with DraftKings and Desus Nice to Launch TUMS Prop Bites, Allowing Big Game Fans to Go All In on Food for the First Time
    • 13.3.2. Dexcel Pharma Acquires 8 OTC Brands to Strengthen its Consumer Healthcare Portfolio
    • 13.3.3. Camber Pharmaceuticals Launches Generic Wellbutrin SR
    • 13.3.4. Reckitt Launches Gaviscon Double Action in Tamil Nadu, Helping People with Acidity and Heartburn
    • 13.3.5. Wonderbelly Expands To Over 1,800 Target Stores to be Easily Accessible to a Broader Audience
    • 13.3.6. Upsher-Smith Launches Famotidine For Oral Suspension
    • 13.3.7. Zydus Secures Final Approval from the USFDA for its Esomeprazole Magnesium Product
    • 13.3.8. Wonderbelly Antacid Brings Exclusive Flavor to Target With Launch
    • 13.3.9. Marksans Pharma Gets USFDA Nod for Famotidine Tablets
    • 13.3.10. ENO Expands its Portfolio with Two New Flavors, Jaljeera and Nimbu Masala

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Aero Healthcare AU Pty Ltd
  • 3. Alcon Industries
  • 4. Alkem Laboratories Ltd.
  • 5. Allegiant Health
  • 6. AstraZeneca plc
  • 7. Bayer AG
  • 8. Biocon Limited
  • 9. Boehringer Ingelheim International GmbH
  • 10. Cadila Pharmaceuticals Limited
  • 11. Camber Pharmaceuticals, Inc.
  • 12. Cipla Limited
  • 13. Daiichi Sankyo Company Limited
  • 14. Dexcel Ltd.
  • 15. Dr. Reddy's Laboratories Ltd.
  • 16. GlaxoSmithKline PLC
  • 17. Haleon PLC
  • 18. Imerys S.A.
  • 19. J. B. Chemicals & Pharmaceuticals Limited
  • 20. Johnson & Johnson Services, Inc.
  • 21. Magmit Pharmaceutical Co., Ltd.
  • 22. Mankind Pharma Ltd.
  • 23. Marksans Pharma
  • 24. Nestle S.A.
  • 25. Novartis AG
  • 26. Perrigo Company plc
  • 27. Pfizer Inc.
  • 28. Raritan Pharmaceuticals, Inc.
  • 29. Reckitt Benckiser Group PLC
  • 30. Sanofi S.A.
  • 31. Sun Pharmaceutical Industries Ltd.
  • 32. Swiss Chem Healthcare by Swastik Lifesciences
  • 33. Takeda Pharmaceutical Company Limited
  • 34. Teva Pharmaceutical Industries Ltd.
  • 35. The Procter & Gamble Company
  • 36. Upsher-Smith Laboratories, LLC by Bora Pharmaceuticals
  • 37. Wonderbelly
  • 38. Zoic Pharmaceuticals Pvt. Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦